Ikerbasque, Fundación Vasca para la Ciencia-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2023

  1. Therapeutic effect of α7 nicotinic receptor activation after ischemic stroke in rats

    Journal of Cerebral Blood Flow and Metabolism, Vol. 43, Núm. 8, pp. 1301-1316

2022

  1. Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55–IL6ST Gene Region in Immature Dendritic Cells

    Frontiers in Immunology, Vol. 12

2018

  1. Inhibition of Casein Kinase 2 Protects Oligodendrocytes From Excitotoxicity by Attenuating JNK/p53 Signaling Cascade

    Frontiers in Molecular Neuroscience, Vol. 11

2015

  1. Cell-specific effects in different immune subsets associated with SOCS1 genotypes in multiple sclerosis

    Multiple Sclerosis, Vol. 21, Núm. 12, pp. 1498-1512

  2. Pharmacogenomic study in patients with multiple sclerosis Responders and nonresponders to IFN-β

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 2, Núm. 5, pp. e154

2014

  1. Autophagic marker MAP1LC3B expression levels are associated with carotid atherosclerosis symptomatology

    PLoS ONE, Vol. 9, Núm. 12

2013

  1. TNFRSF1A polymorphisms rs1800693 and rs4l49584 in patients with multiple sclerosis

    Neurology, Vol. 80, Núm. 22, pp. 2010-2016

2012

  1. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis

    Multiple Sclerosis Journal, Vol. 18, Núm. 7, pp. 983-990